Description
Ansulin 30/70 40 IU Insulin
Indications
This combination injection is indicated for-
Treatment of all patients with type 1 diabetes
Treatment of patients with type 2 diabetes who are not adequately controlled by diet and/ or oral hypoglycemic agents
For the initial stabilization of diabetes in patients with diabetic ketoacidosis, hyperosmolar non-ketotic syndrome and during periods of stress such as severe infections and major surgery in diabetic patients
Treatment of gestational diabetes
Pharmacology
The blood glucose lowering effect of insulin is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. Insulin has a half-life of a few minutes in the blood stream. No profound binding to plasma proteins.
An average action profile after subcutaneous injection indicates:
Onset of action- within 30 minutes
Peak plasma levels attained between 1-3 hours
Duration of action- approximately 18-24 hours
Pharmacology
The blood glucose lowering effect of insulin is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. Insulin has a half-life of a few minutes in the blood stream. No profound binding to plasma proteins.
An average action profile after subcutaneous injection indicates:
Onset of action- within 30 minutes
Peak plasma levels attained between 1-3 hours
Duration of action- approximately 18-24 hours
Reviews
There are no reviews yet.